(RTTNews) -  Thursday, Masimo Corp. (MASI: News ) said it has signed a multi-year technology licensing agreement with CareFusion Corp. (CFN: News ) for establishing the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development.

Masimo said that incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.
Currently, CareFusion uses Masimo technology in the Alaris SpO2 module to help safeguard PCA delivery through the Alaris System. The Alaris PCA module together with the Alaris SpO2 module--featuring Masimo SET pulse oximetry technology for accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements--provides an additional safety net for risk factors not covered by programming safety and bar coding, such as previously undiagnosed clinical conditions and PCA by proxy.

To receive FREE breaking news email alerts for Masimo Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com